<DOC>
	<DOCNO>NCT00325871</DOCNO>
	<brief_summary>Colorectal cancer ( CRC ) one common malignancy worldwide , account significant percentage cancer mortality . Concurrent chemoradiation ( CCRT ) standard treatment unresectable malignancy anorectum . To improve quality life , CCRT also commonly apply treatment lower rectal anal canal cancer preserve anal sphincter function . The commonly use chemotherapeutic drug combine radiation radiosensitizers 5-fluorouracil ( 5-FU ) . Circulating endothelial progenitor cell ( EPC ) , contribute tumor vessel formation , reflect response chemotherapy animal model clinical trial . Thus , circulate EPC use marker optimize monitor anti-angiogenesis therapy include angiogenesis inhibitor chemotherapy . Whether circulate EPC serve marker CCRT efficacy remain undetermined . Since CCRT standard treatment locally advance high-risk CRC , development surrogate marker monitor CCRT response optimize treatment intensity important . In grant intent monitor level circulate EPC locally advance high-risk CRC patient , CCRT . To characterize change function biology EPC cause CCRT , syngeneic animal model also use evaluate clonogenecity specific gene expression EPC tumor-bearing mouse receive CCRT .</brief_summary>
	<brief_title>Chemoradiation Endothelial Progenitor Cells Colorectal Cancer</brief_title>
	<detailed_description>Colorectal cancer ( CRC ) one common malignancy worldwide , account significant percentage cancer mortality . The incidence develop developed country increase past decade ( 1 ) . Radiation therapy , either post-operative adjuvant treatment resectable disease definitive treatment along chemotherapy unresectable disease , important role management cancer ( 1−4 ) . Concurrent chemoradiation ( CCRT ) standard treatment cervical cancer ( bulky locally advanced lesion ) ( 5 ) unresectable malignancy gastrointestinal system origin ( esophagus , stomach , pancreas anorectum ) ( 6−9 ) . To improve quality life , CCRT also commonly apply treatment lower rectal anal canal cancer preserve anal sphincter function ( 9 ) . The commonly use chemotherapeutic drug combine radiation radiosensitizers cis-platinum , 5-fluorouracil ( 5-FU ) mitomycin C ( 6−9 ) . These drug myelosuppressive prone cause life-threatening neutropenia , anemia thrombocytopenia , severe radiotherapy alone ( 5−9 ) . To avoid unnecessary over-treatment CRC , optimization CCRT critical importance . Herein , development surrogate marker monitoring treatment efficacy pivotal optimize CCRT . Angiogenesis heavily regulate process , involve complex interaction inhibitory stimulatory angiogenic factor . It essential tumor growth , progression metastasis correlate poor prognosis cancer patient include CRC . Many novel compound potently inhibit formation neoplastic blood vessel recently develop . There increase interest develop angiogeneis-suppressive agent colorectal cancer treatment grow number anti-angiogenesis drug currently evaluate clinical trial CRC . Promising result report include increase overall survival reduction risk death ( Bevacizumab ) , reversal cellular resistance ( Cetuximab ) activity second-line therapy patient exhaust available treatment option ( Cetuximab , ABX-EGF , PTK-787 , Gefitinib , Erlotinib ) ( 10,11 ) . Although therapeutic role angiogenesis target therapy approve cancer treatment include CRC , way optimize dose angiogenesis inhibitor remain determined lack reliable surrogate marker tumor angiogenesis . Shaked et al . report level circulate endothelial progenitor cell ( EPC ) , contribute tumor vessel formation , reflect anti-tumor efficacy anti-angiogenesis regimen ( 12 ) . Growing evidence suggest level circulate EPC reflect response chemotherapy animal model clinical trial ( 13,14 ) . Thus , circulate EPC use marker optimize monitor anti-angiogenesis therapy include angiogenesis inhibitor chemotherapy . Whether circulate EPC serve marker CCRT efficacy remain undetermined . Since CCRT standard treatment locally advance high-risk CRC , development surrogate marker monitor CCRT response optimize treatment intensity , , important . In grant intent monitor level circulate EPC locally advance high-risk CRC patient , CCRT . To characterize change function biology EPC cause CCRT , syngeneic animal model also use evaluate clonogenecity specific gene expression EPC tumor-bearing mouse receive CCRT . References 1 . Midgley R , Kerr D. Colorectal cancer . Lancet 1999 ; 353:391-399 . 2 . Fisher B , Wolmark N , Rockette H , et al . Postoperative adjuvant chemotherapy radiation therapy rectal cancer : result NSABP protocol R-01 . J Natl Cancer Inst 1988 ; 80:21-29 . 3 . O'Connell MJ , Martenson JA , Wieand HS , et al . Improving adjuvant therapy rectal cancer combine protracted-infusion fluorouracil radiation therapy curative surgery . New Engl J Med 1994 ; 331:502-507 . 4 . Skarlatos J , Kosma L , Koukourakis M , et al . Hypofractionated radiotherapy concurrent 5-fluorouracil radiosensitisation recurrent locally advanced colorectal cancer . A phase II study . Int J Colore Dis 1996 ; 11:206-210 . 5 . Rose PG , Bundy BN , Watkins EB , et al . Concurrent cisplatin-based radiotherapy chemotherapy locally advanced cervical cancer . New Engl J Med 1999 ; 340:1144-1153 . 6. Cooper JS , Guo MD , Herskovic A , et al . Chemoradiotherapy locally advance esophageal cancer : long-term follow-up prospective randomize trial ( RTOG 85-01 ) . Radiation Therapy Oncology Group . J Am Med Assoc 1999 ; 281:1623-1627 . 7 . Henning GT , Schild SE , Stafford SL , et al . Results irradiation chemoirradiation primary unresectable , locally recurrent , grossly incomplete resection gastric adenocarcinoma . Int J Radiat Oncol 2000 ; 46:109-118 . 8 . Mitchell SE , Mendenhall WM , Zlotecki RA , et al . Squamous cell carcinoma anal canal . Int J Radiat Oncol 2001 ; 49:1007-1013 . 9 . Thomas CR , Weiden PL , Traverso LW , et al . Concomitant intraarterial cisplatin , intravenous 5-flourouracil , split-course radiation therapy locally advance unresectable pancreatic adenocarcinoma : phase II study Puget Sound Oncology Consortium ( PSOC-703 ) . Am J Clin Oncol 1997 ; 20:161-165 . 10 . Kelly H. Goldberg RM . Systemic therapy metastatic colorectal cancer : current option , current evidence . Journal Clinical Oncology . 23 ( 20 ) :4553-60 , 2005 11 . Mancuso A. Sternberg CN . Colorectal cancer antiangiogenic therapy : expect clinical practice ? . Critical Reviews Oncology-Hematology . 55 ( 1 ) :67-81 , 2005 Jul . 12 . Schneider M. Tjwa M. Carmeliet P. A surrogate marker monitor angiogenesis last . Cancer Cell . 7 ( 1 ) :3-4 , 2005 . 13 . Bertolini F. Paul S. Mancuso P. Monestiroli S. Gobbi A. Shaked Y. Kerbel RS . Maximum tolerable dose low-dose metronomic chemotherapy opposite effect mobilization viability circulate endothelial progenitor cell . Cancer Research . 63 ( 15 ) :4342-6 , 2003 . 14 . Zhang H. Vakil V. Braunstein M. Smith EL . Maroney J. Chen L. Dai K. Berenson JR. Hussain MM . Klueppelberg U. Norin AJ . Akman HO . Ozcelik T. Batuman OA . Circulating endothelial progenitor cell multiple myeloma : implication significance . Blood . 105 ( 8 ) :3286-94 , 2005</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Colorectal cancer patient indicate chemoradiation With major systemic disease include cancer , diabetes , cardiovacular disease . Received prior chemotherapy radiotherapy within 1 month Receiving immunosuppressant</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>